Novo Nordisk (0QIU) Share Forecast & Price Target

Compare

62 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QIU Analyst Ratings

Moderate Buy

5 Buy

7 Hold

1 Sell

Based on 13 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QIU Stock 12 Month Forecast

Average Price Target

kr565.42

▲(86.20%Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is kr565.42 with a high forecast of kr750.00 and a low forecast of kr375.00. The average price target represents a 86.20% change from the last price of kr303.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"302":"kr302","911":"kr911","454.25":"kr454.3","606.5":"kr606.5","758.75":"kr758.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":750,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr750.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":565.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr565.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr375.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[302,454.25,606.5,758.75,911],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,303.67,338.00307692307695,372.3361538461539,406.6692307692308,441.0023076923077,475.33538461538467,509.66846153846154,544.0015384615385,578.3346153846154,612.6676923076923,647.0007692307693,681.3338461538463,715.666923076923,{"y":750,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,303.67,323.8046153846154,343.9392307692308,364.07384615384615,384.2084615384615,404.3430769230769,424.4776923076923,444.6123076923077,464.74692307692305,484.8815384615384,505.0161538461538,525.1507692307691,545.2853846153846,{"y":565.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,303.67,309.1569230769231,314.64384615384614,320.13076923076926,325.6176923076923,331.1046153846154,336.59153846153845,342.07846153846157,347.56538461538463,353.0523076923077,358.53923076923076,364.0261538461539,369.51307692307694,{"y":375,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":897.26,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":910.1,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":785.08,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":757.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":755.47,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":611.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":601.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":630.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":481.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":431.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":432.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr750.00

Average Price Targetkr565.42

Lowest Price Targetkr375.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Florent CespedesBernstein

Bernstein

kr620

Hold

104.17%

Upside

Reiterated

08/01/25

Bernstein Remains a Hold on Novo Nordisk (0QIU)

Martial DescouturesOddo BHF

Oddo BHF

kr465

Hold

53.13%

Upside

Downgraded

07/30/25

Novo Nordisk downgraded to Neutral from Outperform at Oddo BHFNovo Nordisk downgraded to Neutral from Outperform at Oddo BHF

Sachin JainBank of America Securities

Bank of America Securities

kr550→kr375

Hold

23.49%

Upside

Downgraded

07/30/25

Novo Nordisk downgraded to Neutral from Buy at BofANovo Nordisk downgraded to Neutral from Buy at BofA

David EvansKepler Capital

Kepler Capital

kr630

Buy

107.46%

Upside

Reiterated

07/30/25

Novo Nordisk (0QIU) Receives a Buy from Kepler Capital

Emily FieldBarclays

Barclays

kr700→kr375

Hold

23.49%

Upside

Downgraded

07/30/25

Barclays downgrades Novo Nordisk (0QIU) to a Hold

Elmar KrausDZ BANK AG

DZ BANK AG

―

Hold

―

Reiterated

07/29/25

Novo Nordisk (0QIU) Receives a Hold from DZ BANK AG

Richard VosserJ.P. Morgan

J.P. Morgan

kr650

Buy

114.05%

Upside

Reiterated

07/29/25

J.P. Morgan Remains a Buy on Novo Nordisk (0QIU)

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

kr750

Buy

146.98%

Upside

Reiterated

07/18/25

Deutsche Bank Sticks to Their Buy Rating for Novo Nordisk (0QIU)

Jo WaltonUBS

UBS

kr700→kr600

Buy

97.58%

Upside

Reiterated

07/16/25

UBS Remains a Buy on Novo Nordisk (0QIU)

Kerry HolfordBerenberg Bank

Berenberg Bank

kr610

Hold

100.88%

Upside

Reiterated

07/15/25

Berenberg Bank Remains a Hold on Novo Nordisk (0QIU)

James QuigleyGoldman Sachs

Goldman Sachs

kr775→kr745

Buy

145.33%

Upside

Reiterated

06/30/25

Goldman Sachs Sticks to Their Buy Rating for Novo Nordisk (0QIU)

Benjamin Jackson CFAJefferies

Jefferies

kr415

Sell

36.66%

Upside

Reiterated

06/23/25

Novo Nordisk (0QIU) Gets a Sell from Jefferies

Thibault BoutherinMorgan Stanley

Morgan Stanley

kr550

Hold

81.12%

Upside

Reiterated

06/23/25

Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Nico ChenDBS

DBS

kr330

Sell

8.67%

Upside

Downgraded

04/24/25

Novo Nordisk downgraded to Sell from Buy at DBS BankNovo Nordisk downgraded to Sell from Buy at DBS Bank

Eric Le BerrigaudStifel Nicolaus

Stifel Nicolaus

kr780→kr700

Hold

130.51%

Upside

Downgraded

03/03/25

Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Florent CespedesBernstein

Bernstein

kr620

Hold

104.17%

Upside

Reiterated

08/01/25

Bernstein Remains a Hold on Novo Nordisk (0QIU)

Martial DescouturesOddo BHF

Oddo BHF

kr465

Hold

53.13%

Upside

Downgraded

07/30/25

Novo Nordisk downgraded to Neutral from Outperform at Oddo BHFNovo Nordisk downgraded to Neutral from Outperform at Oddo BHF

Sachin JainBank of America Securities

Bank of America Securities

kr550→kr375

Hold

23.49%

Upside

Downgraded

07/30/25

Novo Nordisk downgraded to Neutral from Buy at BofANovo Nordisk downgraded to Neutral from Buy at BofA

David EvansKepler Capital

Kepler Capital

kr630

Buy

107.46%

Upside

Reiterated

07/30/25

Novo Nordisk (0QIU) Receives a Buy from Kepler Capital

Emily FieldBarclays

Barclays

kr700→kr375

Hold

23.49%

Upside

Downgraded

07/30/25

Barclays downgrades Novo Nordisk (0QIU) to a Hold

Elmar KrausDZ BANK AG

DZ BANK AG

―

Hold

―

Reiterated

07/29/25

Novo Nordisk (0QIU) Receives a Hold from DZ BANK AG

Richard VosserJ.P. Morgan

J.P. Morgan

kr650

Buy

114.05%

Upside

Reiterated

07/29/25

J.P. Morgan Remains a Buy on Novo Nordisk (0QIU)

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

kr750

Buy

146.98%

Upside

Reiterated

07/18/25

Deutsche Bank Sticks to Their Buy Rating for Novo Nordisk (0QIU)

Jo WaltonUBS

UBS

kr700→kr600

Buy

97.58%

Upside

Reiterated

07/16/25

UBS Remains a Buy on Novo Nordisk (0QIU)

Kerry HolfordBerenberg Bank

Berenberg Bank

kr610

Hold

100.88%

Upside

Reiterated

07/15/25

Berenberg Bank Remains a Hold on Novo Nordisk (0QIU)

James QuigleyGoldman Sachs

Goldman Sachs

kr775→kr745

Buy

145.33%

Upside

Reiterated

06/30/25

Goldman Sachs Sticks to Their Buy Rating for Novo Nordisk (0QIU)

Benjamin Jackson CFAJefferies

Jefferies

kr415

Sell

36.66%

Upside

Reiterated

06/23/25

Novo Nordisk (0QIU) Gets a Sell from Jefferies

Thibault BoutherinMorgan Stanley

Morgan Stanley

kr550

Hold

81.12%

Upside

Reiterated

06/23/25

Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Nico ChenDBS

DBS

kr330

Sell

8.67%

Upside

Downgraded

04/24/25

Novo Nordisk downgraded to Sell from Buy at DBS BankNovo Nordisk downgraded to Sell from Buy at DBS Bank

Eric Le BerrigaudStifel Nicolaus

Stifel Nicolaus

kr780→kr700

Hold

130.51%

Upside

Downgraded

03/03/25

Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

1 Month

xxx

Success Rate

35/59 ratings generated profit

Average Return

+0.87%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.32% of your transactions generating a profit, with an average return of +0.87% per trade.

3 Months

xxx

Success Rate

37/59 ratings generated profit

Average Return

+2.18%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.71% of your transactions generating a profit, with an average return of +2.18% per trade.

1 Year

Richard VosserJ.P. Morgan

Success Rate

41/59 ratings generated profit

Average Return

+15.22%

reiterated a buy rating 6 days ago

Copying Richard Vosser's trades and holding each position for 1 Year would result in 69.49% of your transactions generating a profit, with an average return of +15.22% per trade.

2 Years

xxx

Success Rate

33/59 ratings generated profit

Average Return

+14.43%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 55.93% of your transactions generating a profit, with an average return of +14.43% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QIU Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QIU has received 24 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. 0QIU average Analyst price target in the past 3 months is 565.42.

Each month's total comprises the sum of three months' worth of ratings.

0QIU Financial Forecast

0QIU Earnings Forecast

Next quarter’s earnings estimate for 0QIU is kr5.92 with a range of kr4.50 to kr6.50. The previous quarter’s EPS was kr6.53. 0QIU beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 46.74% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.

0QIU Sales Forecast

Next quarter’s sales forecast for 0QIU is kr76.70B with a range of kr72.92B to kr79.54B. The previous quarter’s sales results were kr78.09B. 0QIU beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 51.30% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.

0QIU Stock Forecast FAQ

What is GB:0QIU’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk A/S (UK)’s 12-month average price target is 565.42.

What is GB:0QIU’s upside potential, based on the analysts’ average price target?

Novo Nordisk A/S (UK) has 86.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk A/S (UK) a Buy, Sell or Hold?

Novo Nordisk A/S (UK) has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 7 hold ratings and 1 sell ratings.

What is Novo Nordisk A/S (UK)’s share price target?

The average share price target for Novo Nordisk A/S (UK) is 565.42. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr750.00 ,and the lowest forecast is kr375.00. The average share price target represents 86.20% Increase from the current price of kr303.67.

What do analysts say about Novo Nordisk A/S (UK)?

Novo Nordisk A/S (UK)’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Novo Nordisk A/S (UK)?

To buy shares of GB:0QIU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Novo Nordisk (0QIU) Share Forecast & Price Target

0QIU Analyst Ratings

0QIU Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

0QIU Analyst Recommendation Trends

0QIU Financial Forecast

0QIU Earnings Forecast

0QIU Sales Forecast

0QIU Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts